News Release

Trends in antiepileptic, antipsychotic, and opioid prescribing to nursing home residents with dementia

Peer-Reviewed Publication


An analysis in the Journal of the American Geriatrics Society found that between 2015 and 2019, an increasing proportion of US nursing home residents with Alzheimer’s Disease and related dementias (ADRD) were prescribed antiepileptics, while antipsychotic and opioid prescribing rates declined. 

Also, residents with ADRD and disruptive behaviors were more likely to receive valproic acid (an antiepileptic used as a mood stabilizer), while those with reported pain were more likely to receive gabapentin (an antiepileptic approved to treat nerve pain following shingles but widely prescribed for other pain conditions). 

“Policy-wise, antiepileptics are flying under the radar. Because the evidence base for antiepileptics is relatively weak for both the behavioral and psychological symptoms of dementia and for most pain conditions, these prescribing trends warrant more attention,” said corresponding author Molly Candon, PhD, of the University of Pennsylvania.

URL upon publication:


Additional Information

NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout,

About the Journal

Journal of the American Geriatrics Society (JAGS) is the go-to journal for clinical aging research. We provide a diverse, interprofessional community of healthcare professionals with the latest insights on geriatrics education, clinical practice, and public policy—all supporting the high-quality, person-centered care essential to our well-being as we age. 

About Wiley

Wiley is one of the world’s largest publishers and a global leader in scientific research and career-connected education. Founded in 1807, Wiley enables discovery, powers education, and shapes workforces. Through its industry-leading content, digital platforms, and knowledge networks, the company delivers on its timeless mission to unlock human potential. Visit us at Follow us on FacebookTwitterLinkedIn and Instagram.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.